MasTec enters the week with an interesting split: the stock has rallied 4.6% over the past five days to $369.35, yet it remains down nearly 11% over the past month — and short sellers have been adding exposure throughout.
The positioning picture is unambiguous on direction, if modest in scale. Short interest has climbed for four consecutive weeks, rising 3.6% over the past week and nearly 9% over the past month to reach 4.3% of the free float. That is not an extreme level — it ranks in just the 34th percentile on ORTEX's short-score factor — but the trend is consistent. Crucially, the borrow market tells you this is a considered directional bet, not a squeeze-driven technical position. Availability is extraordinarily loose: over 46 million shares are available to lend against roughly 3.3 million shorted, putting the availability ratio above 5,000% — effectively unlimited supply for new shorts. Cost to borrow is a negligible 0.39%, down from 0.51% two weeks ago despite a 47% rise over the past month. Nothing in the lending market suggests stress. Options are equally calm. The put/call ratio of 0.60 sits less than one standard deviation above its 20-day average of 0.55, well within normal range and far below its 52-week peak of 2.16. Positioning overall looks cautious rather than crowded.
The Street, by contrast, remains firmly in the bull camp. All 17 analysts tracked carry buy-equivalent ratings, and the cluster of upgrades and target increases that followed the May earnings print was unusually synchronized. Multiple firms pushed targets sharply higher: Cantor Fitzgerald went from $347 to $545, Goldman Sachs from $348 to $487, TD Cowen from $320 to $445. Guggenheim upgraded from Neutral to Buy with a $480 target. The consensus mean sits at $473, implying roughly 28% upside from current levels — though that consensus is now about four weeks stale and predates the stock's recent 11% pullback. The bull case centres on three concurrent infrastructure mega-cycles: energy transition, communications buildout, and data centre construction. Bears acknowledge the backlog strength but flag premium valuation and labour availability risk; the EV/EBITDA multiple of 18.7x and a PE near 36 leave limited margin for execution misses. The EV/EBIT factor ranks in just the 16th percentile on ORTEX's universe, flagging the valuation tension explicitly.
One ownership angle worth noting: the institutional picture has seen some active new entrants. Peconic Partners added nearly 2 million shares in Q1 to hold a 4.6% stake, while Lone Pine Capital initiated a position of 1.5 million shares in the same period. Vanguard's two separate vehicles combined added over 5.5 million shares. Against that institutional accumulation, recent insider activity leans the other way. CEO Jose Mas sold 28,184 shares in March at $297.81, a $8.4 million transaction. COO Robert Apple sold 12,206 shares in the same window. More recently, independent director Ernst Csiszar sold 6,500 shares on June 3rd at $371.17 for $2.4 million — the most significant insider sale in the current price range. Net insider activity over the past 90 days shows positive share flow of roughly 71,000 shares, but that reflects the aggregate across a period when the stock ranged widely; the executive-level sells at elevated prices are the more telling signal.
MasTec's next earnings event is scheduled for August 6. The recent print history gives reason for patience: the May 1 report produced a 7.9% single-day gain and a 5.1% five-day follow-through, while earlier prints have been mixed, including a 5-day loss of 8.6% after the February result. With the stock now trading nearly $100 below the analyst consensus target but still carrying a stretched valuation multiple, the August print becomes the focal point — specifically whether the backlog conversion and margin improvement in the Pipeline and Power Delivery segments are tracking the ambitious 2028 targets the Street has priced in.
See the live data behind this article on ORTEX.
Open MTZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
